Pharmacokinetics of salsalate and salicylic acid in normal and diabetic rats

Biopharmaceutics and Drug Disposition

Volumn 33, Issue 6, 2012, Pages 285-291

  Cao, Yanguang ^a   Dubois, Debra C ^a   Almon, Richard R ^a   Jusko, William J ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

diabetes; pharmacokinetics; salicylic acid; salsalate

Indexed keywords

SALICYLIC ACID; SALSALATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HYDROLYSIS; DRUG MEGADOSE; DRUG TRANSFORMATION; GOTO KAKIZAKI RAT; MALE; MEAN RESIDENCE TIME; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RAT; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL AVAILABILITY; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; HYDROLYSIS; HYPOGLYCEMIC AGENTS; INJECTIONS, INTRAVENOUS; LINEAR MODELS; MALE; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; RATS; RATS, WISTAR; SALICYLATES; SALICYLIC ACID;

EID: 84866256196     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.1797     Document Type: Article

References (18)

1. Faghihimani E, Aminorroaya A, Rezvanian H, Adibi P, Ismail-Beigi F, Amini M,. Salsalate improves glycemic control in patients with newly diagnosed type 2 diabetes. Acta Diabetol 2011. doi: 10.1007/s00592-011-0329-2.
2. Goldfine AB, Silver R, Aldhahi W, et al,. Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clin Transl Sci 2008; 1: 36-43.
3. Koska J, Ortega E, Bunt JC, et al,. The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study. Diabetologia 2009; 52: 385-393.
4. Cao Y, DuBois DC, Sun H, Almon RR, Jusko WJ,. Modeling diabetes disease progression and salsalate intervention in Goto-Kakizaki rats. J Pharmacol Exp Ther 2011; 339: 896-904.
5. Fleischman A, Shoelson SE, Bernier R, Goldfine AB,. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care 2008; 31: 289-294. (Pubitemid 351213338)
6. Desouza CV,. An overview of salsalate as a potential antidiabetic therapy. Drugs Today (Barc) 2010; 46: 847-853.
7. Nelson E, Hanano M, Levy G,. Comparative pharmacokinetics of salicylate elimination in man and rats. J Pharmacol Exp Ther 1966; 153: 159-166.
8. Varma DR, Yue TL,. Influence of age, sex, pregnancy and protein-calorie malnutrition on the pharmacokinetics of salicylate in rats. Br J Pharmacol 1984; 82: 241-248. (Pubitemid 14149451)
9. Dromgoole SH, Cassell S, Furst DE, Paulus HE,. Availability of salicylate from salsalate and aspirin. Clin Pharmacol Ther 1983; 34: 539-545. (Pubitemid 13016987)
10. Harrison LI, Funk ML, Ober RE,. High-pressure liquid chromatographic determination of salicylsalicylic acid, aspirin, and salicylic acid in human plasma and urine. J Pharm Sci 1980; 69: 1268-1271. (Pubitemid 11162716)
11. Savic RM, Jonker DM, Kerbusch T, Karlsson MO,. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn 2007; 34: 711-726. (Pubitemid 47477040)
12. D'Argenio DZ, Schumitzky A,. ADAPT V User's Guide: Pharmacokinetic/ Pharmacodynamic System Analysis Software. Biomedical Simulations Resource, Los Angeles, CA, 2009.
13. Davies B, Morris T,. Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10: 1093-1095. (Pubitemid 23211439)
14. Wiegand UW, Levy G,. Effect of heparin injection on plasma protein binding of bilirubin and salicylate in rats. J Pharm Sci 1979; 68: 1483-1486. (Pubitemid 10183427)
15. Sawamoto T, Haruta S, Kurosaki Y, Higaki K, Kimura T,. Prediction of the plasma concentration profiles of orally administered drugs in rats on the basis of gastrointestinal transit kinetics and absorbability. J Pharm Pharmacol 1997; 49: 450-457. (Pubitemid 27207703)
16. Levy G, Jusko WJ,. Effect of viscosity on drug absorption. J Pharm Sci 1965; 54: 219-224.
17. Beig A, Miller JM, Dahan A,. Accounting for the solubility-permeability interplay in oral formulation development for poor water solubility drugs: The effect of PEG-400 on carbamazepine absorption. Eur J Pharm Biopharm 2012; 81: 386-391.
18. Gwilt PR, Nahhas RR, Tracewell WG,. The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans. Clin Pharmacokinet 1991; 20: 477-490.